China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company’s high-end product pipeline, APIs research and development, medical consumables CDMO services, and the construction of a global omni-channel network.
Company Overview and Focus Areas
Founded in 2020, Acumen Bio is a leading player in the design, research and development, manufacturing, and marketing of high-end consumables and packaging materials. The company operates across various sectors, including life sciences, agriculture and animal husbandry, medical diagnosis, and drug research and development. In addition to its consumables, Acumen Bio offers comprehensive solutions and CDMO services, positioning itself as a one-stop solution provider in its field.
Strategic Use of Funds for Growth and Expansion
The proceeds from the Series A+ financing round will be instrumental in fueling Acumen Bio’s growth strategy. The company plans to expand its high-end product pipeline, which is crucial for maintaining a competitive edge in the market. Investments in APIs research and development will enhance the company’s innovation capabilities, while the expansion of medical consumables CDMO services will cater to the growing demand for customized and specialized products.
Global Omni-Channel Construction
A significant portion of the funds will be directed towards the construction of a global omni-channel network. This initiative will enable Acumen Bio to broaden its reach and establish a stronger presence in international markets, providing the company with access to a wider customer base and facilitating the distribution of its products and services on a global scale.-Fineline Info & Tech
